Highly active antiretroviral therapy (HAART)

DRUG5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Johns Hopkins Bloomberg School of Public Health, Massachusetts General Hospital, International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Vertex Pharmaceuticals Incorporated

Conditions

HIV InfectionHIV InfectionsHepatitis C

Phase 1

Effectiveness of Antiretroviral Therapy During Acute HIV Infection

CompletedNCT00705926

Massachusetts General HospitalHIV Infections

Start: 2008-10-31End: 2017-07-16Updated: 2017-08-31

Phase 2

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

CompletedNCT00031343

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis C, HIV Infections

Start: 2002-02-28End: 2004-04-30Target: 128Updated: 2008-03-04

Phase 3

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

TerminatedNCT01467479

Vertex Pharmaceuticals IncorporatedHepatitis C

Start: 2011-12-31End: 2014-02-28Updated: 2015-03-17

Phase 4

Anti-HIV Medications for People Recently Infected With HIV

CompletedNCT00106171

Johns Hopkins Bloomberg School of Public HealthHIV Infections

Start: 2005-05-31End: 2012-05-31Updated: 2023-09-13

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

CompletedNCT00955968

International Maternal Pediatric Adolescent AIDS Clinical Trials GroupHIV Infection

Start: 2010-01-01End: 2016-08-31Updated: 2023-08-14

Related Papers

Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3

PLoS ONE2017-05-1025 citations

A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection

PLoS ONE2015-11-241 citations